{"id":"NCT01165229","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older","officialTitle":"Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08-02","primaryCompletion":"2015-07-24","completion":"2015-07-24","firstPosted":"2010-07-19","resultsPosted":"2017-11-20","lastUpdate":"2020-04-27"},"enrollment":14819,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster","Herpes Zoster Vaccine"],"interventions":[{"type":"BIOLOGICAL","name":"Herpes Zoster Vaccine GSK1437173A","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Zoster vaccine group","type":"EXPERIMENTAL"},{"label":"Placebo group","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged â‰¥ 70 years.\n\nTwo studies (Zoster-006 \\[NCT01165177\\] and Zoster-022 \\[NCT01165229\\]) will be conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. This protocol posting also deals with the outcome measures related to the pooled analysis.","primaryOutcome":{"measure":"Number of Subjects With Any Episodes of Herpes Zoster (HZ)","timeFrame":"During the entire study period (3 to 5 year period following Day 0)","effectByArm":[{"arm":"Zoster-022 GSK1437173A 70-79YOA Group","deltaMin":17,"sd":null},{"arm":"Zoster-022 GSK1437173A >=80YOA Group","deltaMin":6,"sd":null},{"arm":"Zoster-022 GSK1437173A >=70YOA Group","deltaMin":23,"sd":null},{"arm":"Zoster-022 Placebo 70-79YOA Group","deltaMin":169,"sd":null},{"arm":"Zoster-022 Placebo >=80YOA Group","deltaMin":54,"sd":null},{"arm":"Zoster-022 Placebo >=70YOA Group","deltaMin":223,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.0001"},{"comp":"OG001 vs OG004","p":"<0.0001"},{"comp":"OG002 vs OG005","p":"<0.0001"}]},"eligibility":{"minAge":"70 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":213,"countries":["United States","Australia","Brazil","Canada","Czechia","Estonia","Finland","France","Germany","Hong Kong","Italy","Japan","Mexico","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["27626517","29529222","29463421","37166199","36066965","33606577","32910152","32347767","31537443","30935742","29955836"],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1153,"n":6950},"commonTop":["Injection site pain","Injection site erythema","Headache","Fatigue","Injection site swelling"]}}